The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty

Acta Anaesthesiologica Scandinavica

Volumn 49, Issue 10, 2005, Pages 1491-1500

  Chan, Vincent W S ^a   Clark, A J ^b   Davis, J C ^c   Wolf, R S ^c   Kellstein, D ^d   Jayawardene, S ^d  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b Chronic Pain Centre   (Canada)

^c Capstone Clinical Trials Inc   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Arthroplasty; COX 2 inhibitor; Lumiracoxib; Naproxen; Post operative pain; Selective cyclooxygenase 2 inhibitor

Indexed keywords

IBUPROFEN; LUMIRACOXIB; MORPHINE SULFATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETHIDINE; PLACEBO; PROMETHAZINE;

ADULT; AGED; ANALGESIA; ANEMIA; ARTICLE; BLEEDING; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTENSION; HYPOXIA; INSOMNIA; MALE; NAUSEA; PLEURA EFFUSION; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PRURITUS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; TACHYCARDIA; THORAX PAIN; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT WITHDRAWAL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NAPROXEN; ORGANIC CHEMICALS; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; SAMPLE SIZE;

EID: 27644453938     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2005.00782.x     Document Type: Article

References (33)

1. Sinatra RS, Torres J, Bustos AM. Pain management after major orthopaedic surgery: current strategies and new concepts. J Am Acad Orthop Surg 2002; 10: 117-29.
2. Sinatra RS. Role of COX-2 inhibitors in the evolution of acute pain management. J Pain Symptom Manage 2002; 24 (Suppl. 1): S18-S27.
3. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-7.
4. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987; 1: 89-96.
5. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-99.
6. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclooxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 458-61.
7. Gimbel JS, Brugger A, Zhao W, Verburg KM, Geis GS. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001; 23: 228-41.
8. Reicin A, Brown J, Jove M, de Andrade JR, Bourne M, Krupa D et al. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am J Orthop 2001; 30: 40-8.
9. Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 1876-83.
10. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-33.
11. Katz WA. Cyclooxygenase-2-selective inhibitors in the management of acute and perioperative pain. Cleve Clin J Med 2002; 69 (Suppl. 1): S165-S175.
12. Afflitto L. Selective COX-2 inhibitors and the surgical patient. Plast Surg Nurs 2000; 20: 91-3.
13. Marshall PJ, Berry JC, Wasvary J, Van Duzer J, Scott J, Rordorf C et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002; 61 (Suppl. 1): 259.
14. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004; 32: 566-71.
15. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavlijev S et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004; 43: 467-78.
16. Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SJ, Senftleber I et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2004; 51: 549-57.
17. Tannenbaum H, Berenbaum F, Reginster J-Y, Zacher J, Robinson J, Poor G et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis 2004; 63: 1419-26.
18. Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore A et al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin Exp Rheumatol 2004; 22: 589-96.
19. Zelenakas K, Fricke J Jr, Jayawardene S, Kellstein D. Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. Int J Clin Pract 2004; 58: 251-6.
20. Kellstein D, Ott D, Jayawardene S, Fricke J Jr. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of postoperative dental pain. Int J Clin Pract 2004; 58: 244-50.
21. Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. Clin Gastroenterol Hepatol 2004; 2: 113-20.
22. Hawkey CJ, Svoboda P, Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin M et al. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 2004; 31: 1804-10.
23. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E et al (TARGET Study Group). Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
24. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ et al (TARGET Study Group). Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-84.
25. Miller RG. Survival Analysis. New York: Wiley, 1981: 74-5.
26. Warfield CA, Kahn CH. Acute pain management. Programs in U.S. hospitals and experiences and attitudes among U.S. adults. Anesthesiology 1995; 83: 1090-4.
27. Stephens J, Laskin B, Pashos C, Pena B, Wong J. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology 2003; 42 (Suppl. 3): 40-52.
28. Baber SR, Hyman AL, Kadowitz PJ. Role of COX-1 and -2 in prostanoid generation and modulation of angiotensin II responses. Am J Physiol Heart Circ Physiol 2003; 285: H2399-H2410.
29. Reuben SS, Fingeroth R, Krushell R, Maciolek H. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002; 17: 26-31.
30. Silverman DG, Halaszynski T, Sinatra R, Luther M, Rinder CS. Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. Can J Anaesth 2003; 50: 1004-8.
31. Scott G, Rordorf C, Milosavljev S, Chase W, Fleischmann RM, Kivitz AJ et al. Multiple-dose lumiracoxib shows rapid absorption and COX-2 selectivity without accumulation in patients with rheumatoid arthritis. In: Tulunay FC, Orme M, eds. European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer-Verlag, 2003: 124.
32. Scott G, Rordorf C, Milosavljev S, Ferber G. Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis. Ann Rheum Dis 2002; 61 (Suppl. 1): 128.
33. Fricke J, Zelenakas K, Jayawardene S, Manning D. Efficacy of COX189 compared to rofecoxib in the treatment of postoperative dental pain: a double-blind, randomized, placebo-controlled trial. In: World Congress on Pain (WCP) 2002, August 17-22, San Diego, CA:223.